The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.
The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor
* Appropriate candidate for treatment with tarlatamab based on investigator discretion
* Age \> 18 years
* Signed written informed consent including HIPAA according to institutional guidelines
Exclusion Criteria:
* Does not meet all inclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is focused on collecting blood samples to study how tarlatamab behaves in real-world patients rather than testing a new treatment, does this mean I would already need to be receiving tarlatamab as part of my care before this study would even be relevant to me?
2This trial isn't yet recruiting — do you have a sense of when it might open, and would it make sense to consider tarlatamab as a treatment option for my small-cell lung cancer first, separate from this study?
3Because this study's main goal is analyzing blood samples to better understand tarlatamab in real-world settings, what does the blood collection schedule actually look like in practice, and how frequently would I need to come in for draws on top of my regular treatment visits?
4Since this appears to be a data-collection study rather than a phase testing safety or efficacy of a new drug, does participating in this trial offer me any direct treatment benefit, or is it primarily contributing to research that helps future patients?
5If tarlatamab is something you'd consider for my treatment plan, would you recommend I pursue it as standard care first, and then decide separately whether to join this blood collection study once it opens?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of blood samples collected to better characterize tarlatamab in real-world setting
Timeframe: Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment